Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B

Environmental Toxicology and Pharmacology

Volumn 36, Issue 2, 2013, Pages 600-610

  Rogalska, Aneta ^a   Szula, Ewa ^a   Gajek, Arkadiusz ^a   Marczak, Agnieszka ^a   Jóźwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Epothilone B; Human ovarian cell lines; Paclitaxel

Indexed keywords

CALCIUM; CYTOCHROME C; EPOTHILONE B; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TUMOR MARKER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CELL METABOLISM; CELL STRAIN; CELL STRAIN MM 14; CELL STRAIN OV 90; CELL STRUCTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

2′,7′-DICHLORODIHYDROFLUORESCEIN DIACETATE; 5,5′6,6′-TETRACHLORO-1,1′3,3′-TETRAETHYL-BENZIMIDAZOL-CARBOCYANINE IODIDE; APOPTOSIS; DCFH(2)-DA; EPO B; EPOTHILONE B; HUMAN OVARIAN CELL LINES; JC-1; PACLITAXEL; PTX;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM; CELL LINE, TUMOR; CELL SHAPE; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; OVARIAN NEOPLASMS; OVARY; PACLITAXEL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; TUBULIN MODULATORS;

EID: 84880345015     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.06.003     Document Type: Article

References (53)

1. Alexandre J., Batteux F., Nicco C., Chereau C., Laurent A., Guillevin L., Weill B., Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int. J. Cancer 2006, 119:41-48.
2. Asada S., Fukuda K., Nishisaka F., Matsukawa M., Hamanisi C. Hydrogen peroxide induces apoptosis of chondrocytes; involvement of calcium ion and extracellular signal-regulated protein kinase. Inflamm. Res. 2001, 50:19-23.
3. Bystricky B., Chau I. Patupilone in cancer treatment. Expert Opin. Invest. Drugs 2011, 20:107-117.
4. Carmichael J., Degraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay - assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
5. Carmichael J., Degraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay - assessment of radiosensitivity. Cancer Res. 1987, 47:943-946.
6. Chen J., Chen Y., Chen Z. MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest. 2013, 31:17-23.
7. Denk G.U., Kleiss C.P., Wimmer R., Vennegeerts T., Reiter F., Schulz S., Zischka H., Rust C. Tauro-beta-muricholic acid restricts bile acid-induced hepatocellular apoptosis by preserving the mitochondrial membrane potential. Biochem. Biophys. Res. Commun. 2012, 424:758-764.
8. Diaz-Padilla I., Oza A.M. Epothilones in the treatment of ovarian cancer. Future Oncol. 2011, 7:559-568.
9. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35:495-516.
10. Fauzee N.J., Wang Y.L., Dong Z., Li Q.G., Wang T., Mandarry M.T., Xu L., Pan J. Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines. Cell Proliferat. 2012, 45:352-364.
11. Fernandez Y., Cueva J., Palomo A.G., Ramos M., de Juan A., Calvo L., Garcia-Mata J., Garcia-Teijido P., Pelaez I., Garcia-Estevez L. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat. Rev. 2010, 36:33-42.
12. Ferrandina G., Mariani M., Andreoli M., Shahabi S., Scambia G., Ferlini C. Novel drugs targeting microtubules: the role of epothilones. Curr. Pharm. Des. 2012, 18:2793-2803.
13. Fitzgerald D.P., Emerson D.L., Qian Y., Anwar T., Liewehr D.J., Steinberg S.M., Silberman S., Palmieri D., Steeg P.S. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol. Cancer Ther. 2012, 11:1959-1967.
14. Fojo T., Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann. Oncol. 2007, 18(Suppl. 5):v3-v8.
15. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition 2012.
16. Gan P.P., McCarroll J.A., Byrne F.L., Garner J., Kavallaris M. Specific beta-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS ONE 2011, 6:e21717.
17. Gasiorowski K., Brokos B., Kulma A., Ogorzalek A., Skorkowska K. A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. Cell. Mol. Biol. Lett. 2001, 6:141-159.
18. (2+) and apoptosis. Cell Calcium 2012, 52:36-43.
19. 2+ signaling, mitochondria and cell death. Curr. Mol. Med. 2008, 8:119-130.
20. Goodin S. Novel cytotoxic agents: epothilones. Am. J. Health Syst. Pharm. 2008, 65:S10-S15.
21. Guo F., Nimmanapalli R., Paranawithana S., Wittman S., Griffin D., Bali P., O'Bryan E., Fumero C., Wang H.G., Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002, 99:3419-3426.
22. Halliwell B., Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br. J. Pharmacol. 2004, 142:231-255.
23. Hamm-Alvarez S., Cadenas E. Mitochondrial medicine and mitochondrion-based therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1437-1438.
24. Hammer S., Sommer A., Fichtner I., Becker M., Rolff J., Merk J., Klar U., Hoffmann J. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin. Cancer Res. 2010, 16:1452-1465.
25. Hempel S.L., Buettner G.R., O'Malley Y.Q., Wessels D.A., Flaherty D.M. Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: comparison with 2',7'-dichlorodihydrofluorescein diacetate, 5(and 6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. Free Radical. Biol. Med. 1999, 27:146-159.
26. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann. Oncol. 2006, 17:735-749.
27. Horio M., Kato T., Mii S., Enomoto A., Asai M., Asai N., Murakumo Y., Shibata K., Kikkawa F., Takahashi M. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer. Cancer Med. 2012, 1:218-229.
28. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
29. Jakobisiak M., Lasek W., Golab J. Natural mechanisms protecting against cancer. Immunol. Lett. 2003, 90:103-122.
30. Jeong J.Y., Kim K.S., Moon J.S., Song J.A., Choi S.H., Kim K.I., Kim T.H., An H.J. Targeted inhibition of phosphatidyl inositol-3-kinase p110beta, but not p110alpha, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis 2013.
31. Kania K., Zych A., Jozwiak Z. Involvement of reactive oxygen species in aclarubicin-induced death of human trisomic and diabetic fibroblasts. Toxicol. In Vitro 2007, 21:1010-1019.
32. Khawaja N.R., Carre M., Kovacic H., Esteve M.A., Braguer D. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol. Pharmacol. 2008, 74:1072-1083.
33. Kluck R.M., McDougall C.A., Harmon B.V., Halliday J.W. Calcium chelators induce apoptosis-evidence that raised intracellular ionised calcium is not essential for apoptosis. Biochim. Biophys. Acta 1994, 1223:247-254.
34. Kobayashi C.I., Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J. Cell. Physiol. 2012, 227:421-430.
35. Lee J.J., Swain S.M. The epothilones: translating from the laboratory to the clinic. Clin. Cancer Res. 2008, 14:1618-1624.
36. Lee S.H., Son S.M., Son D.J., Kim S.M., Kim T.J., Song S., Moon D.C., Lee H.W., Ryu J.C., Yoon D.Y., Hong J.T. Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. Mol. Cancer Ther. 2007, 6:2786-2797.
37. Magnani M., Ortuso F., Soro S., Alcaro S., Tramontano A., Botta M. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J. 2006, 273:3301-3310.
38. Mhaidat N.M., Alali F.Q., Matalqah S.M., Matalka I.I., Jaradat S.A., Al-Sawalha N.A., Thorne R.F. Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78. Anticancer Drugs 2009, 20:601-606.
39. Mhaidat N.M., Thorne R., Zhang X.D., Hersey P. Involvement of endoplasmic reticulum stress in docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis 2008, 13:1505-1512.
40. O'Reilly T., McSheehy P.M., Wartmann M., Lassota P., Brandt R., Lane H.A. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 2011, 22:58-78.
41. Oehler C., von Bueren A.O., Furmanova P., Broggini-Tenzer A., Orlowski K., Rutkowski S., Frei K., Grotzer M.A., Pruschy M. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro Oncol. 2011, 13:1000-1010.
42. Pellicciotta I., Yang C.P., Goldberg G.L., Shahabi S. Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells. Gynecol. Oncol. 2011, 122:625-631.
43. Pellicciotta I., Yang C.P., Venditti C.A., Goldberg G.L., Shahabi S. Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int. 2013, 13:33.
44. Rogalska A., Koceva-Chyla A., Jozwiak Z. Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem. Biol. Interact. 2008, 176:58-70.
45. Rogalska A., Marczak A., Gajek A., Szwed M., Sliwinska A., Drzewoski J., Jozwiak Z. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol. In Vitro 2013, 27:239-249.
46. Shprung T., Gozes I. A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. J. Mol. Neurosci. 2009, 37:254-262.
47. Tanaka T., Toujima S., Utsunomiya T., Yukawa K., Umesaki N. Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery. Oncol. Rep. 2008, 20:13-23.
48. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
49. Wang H., Yang X., Zhang Z., Xu H. Both calcium and ROS as common signals mediate Na(2)SeO(3)-induced apoptosis in SW480 human colonic carcinoma cells. J. Inorg. Biochem. 2003, 97:221-230.
50. Wang J., Zhang H., Ying L., Wang C., Jiang N., Zhou Y., Wang H., Bai H. Five new epothilone metabolites from Sorangium cellulosum strain So0157-2. J. Antibiot. (Tokyo) 2009, 62:483-487.
51. Wang S., Xiao W., Shan S., Jiang C., Chen M., Zhang Y., Lu S., Chen J., Zhang C., Chen Q., Long M. Multi-patterned dynamics of mitochondrial fission and fusion in a living cell. PLoS ONE 2012, 7:e19879.
52. Winsel S., Sommer A., Eschenbrenner J., Mittelstaedt K., Klar U., Hammer S., Hoffmann J. Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells. PLoS ONE 2011, 6:e19273.
53. Wu K.D., Cho Y.S., Katz J., Ponomarev V., Chen-Kiang S., Danishefsky S.J., Moore M.A. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:10640-10645.